Travere Therapeutics (NASDAQ:TVTX) Reaches New 12-Month High on Analyst Upgrade

Travere Therapeutics, Inc. (NASDAQ:TVTX) shares reached a new 52-week high on Tuesday after Piper Sandler upgraded the stock from a neutral rating to an overweight rating. Piper Sandler now has a $49.00 price target on the stock. Travere Therapeutics traded as high as $42.50 and last traded at $40.9950, with a volume of 4970206 shares changing hands. The stock had previously closed at $30.70.

Several other equities analysts have also weighed in on TVTX. JPMorgan Chase & Co. reduced their price target on shares of Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a research report on Wednesday, March 25th. Canaccord Genuity Group upped their price objective on shares of Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday. Citigroup upped their price objective on shares of Travere Therapeutics from $48.00 to $53.00 and gave the company a “buy” rating in a report on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Finally, Wedbush upped their price objective on shares of Travere Therapeutics from $39.00 to $44.00 and gave the company an “outperform” rating in a report on Tuesday. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.50.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, insider Jula Inrig sold 1,779 shares of the company’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $32.21, for a total transaction of $57,301.59. Following the sale, the insider directly owned 105,706 shares of the company’s stock, valued at $3,404,790.26. This represents a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Roy D. Baynes sold 10,000 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $33.00, for a total transaction of $330,000.00. Following the sale, the director directly owned 37,500 shares in the company, valued at approximately $1,237,500. This trade represents a 21.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 312,067 shares of company stock valued at $9,755,570. Insiders own 4.06% of the company’s stock.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: U.S. FDA expanded / granted full approval of FILSPARI (sparsentan) as the first approved medicine for FSGS — the company’s lead commercial asset and the main fundamental catalyst behind today’s rally. Business Wire: FILSPARI approval Reuters: FDA expands approval
• Positive Sentiment: Multiple brokerages raised ratings and price targets after the approval: Canaccord raised its PT to $56 (buy), Guggenheim to $54 (buy), Piper Sandler upgraded to overweight with a $49 PT, Wedbush raised its PT to $44 (outperform), and HC Wainwright reaffirmed buy at $47 — collectively signaling stronger sell-side conviction and added buy-side interest. Benzinga: analyst moves
• Positive Sentiment: Unusually large call-option activity: traders bought ~21,305 calls on Monday (≈552% above normal), indicating speculative/hedged bullish positioning ahead of or on the news. This options flow likely amplified intraday upside. (No single-source link provided in feed.)
• Neutral Sentiment: Trading was temporarily halted for TVTX with a “news pending” halt prior to the announcement — a procedural move that often precedes major company or regulatory news and can concentrate volume when trading resumes.

Institutional Investors Weigh In On Travere Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TVTX. Stephens Investment Management Group LLC purchased a new stake in shares of Travere Therapeutics in the third quarter worth about $38,232,000. State Street Corp lifted its holdings in shares of Travere Therapeutics by 47.8% in the fourth quarter. State Street Corp now owns 4,756,666 shares of the company’s stock worth $181,752,000 after buying an additional 1,538,827 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Travere Therapeutics by 3,331.9% in the third quarter. Wellington Management Group LLP now owns 1,201,469 shares of the company’s stock worth $28,715,000 after buying an additional 1,166,460 shares in the last quarter. Fiera Capital Corp purchased a new stake in shares of Travere Therapeutics in the fourth quarter worth about $33,398,000. Finally, Perceptive Advisors LLC purchased a new stake in shares of Travere Therapeutics in the second quarter worth about $12,347,000.

Travere Therapeutics Stock Performance

The stock has a market capitalization of $3.89 billion, a PE ratio of -140.43 and a beta of 0.86. The company has a debt-to-equity ratio of 2.71, a current ratio of 2.74 and a quick ratio of 2.70. The business’s fifty day moving average price is $29.38 and its 200-day moving average price is $31.30.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.